Development and use of integral assays in clinical trials - Wikidata - awgldk - TriplyDB

Development and use of integral assays in clinical trials

Development and use of integral assays in clinical trials

http://www.wikidata.org/entity/Q35838558

about

Molecular biomarkers for grass pollen immunotherapy.Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development Bridging the gap: moving predictive and prognostic assays from research to clinical use Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031 Biomarker development in the context of urologic cancers Publicly funded clinical trials and the future of cancer care Protein and peptide biomarkers in organ transplantation.Validation and clinical utility of prostate cancer biomarkers.Developing translational research infrastructure and capabilities associated with cancer clinical trials.Current status of molecular biomarkers in endometrial cancer.Whole-Exome Sequencing and Whole-Genome Sequencing in Critically Ill Neonates Suspected to Have Single-Gene Disorders.Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.Pathology in drug discovery and development.

P2860

Q34093047-12C7DBA6-763D-4F53-8102-FF8C5B6B4667 Q35042433-4B0E1B39-1DDC-40AD-A3B9-775DC090E1E5 Q35838562-6DB29834-AF58-4E87-9E8A-2FB9C2968798 Q35838577-38676F5E-1123-429A-AE6D-085B489D2DBF Q35840045-2CCF7CE8-A977-47AE-97EE-251A0FE42268 Q35848149-8185935C-E49F-42CC-8CE0-522793DCAC1A Q35906352-D4380AA0-0713-4720-933E-D3EEB4AC50A9 Q36630481-A1261125-1056-4540-A74E-B51C9CD41B7F Q38021513-30714D26-D7E7-4C51-8C84-9898E3D35F2B Q38086420-12BF77F1-C3F8-490B-83EF-99997CE354DD Q38145438-893C320E-A6C3-4B75-A89C-52CEB02650D6 Q38234228-224B367C-9A8E-49CB-8192-8E7360A1FD46 Q38673804-FAF2B306-57D9-4DC0-97FD-73C740F00190 Q38817134-1717C27E-F463-4AEA-808C-42FDC42209EF Q48615889-9C02CE8E-D3AA-4E89-86FB-0851EFD724B4

P2860

Development and use of integral assays in clinical trials

http://www.wikidata.org/entity/Q35838558

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Development and use of integral assays in clinical trials

@ast

Development and use of integral assays in clinical trials

@en

type

label

Development and use of integral assays in clinical trials

@ast

Development and use of integral assays in clinical trials

@en

prefLabel

Development and use of integral assays in clinical trials

@ast

Development and use of integral assays in clinical trials

@en

P1433

Q35838558-3C51A459-9186-4B18-A0EC-AB0E8B111EE0

P1476

Q35838558-ACBA1F5F-FD15-467F-80DF-60864A520AA3

P2093

Q35838558-56D3C6FE-C7A8-4CA8-BFA8-14C1D6E125A3

Q35838558-9052B39B-D7DA-46C3-B76A-8C31BCB0919B

Q35838558-F2DE0DD5-6FA1-420A-A039-97FA74D36A81

Q35838558-F4DB869E-84B9-4485-A81F-7BFB0C31AC26

P2860

Q35838558-06E2882D-906E-4076-BC6B-A9DCE4A788BE

Q35838558-1F874D53-A4CB-42CD-8078-825941B980AA

Q35838558-229DDD1F-2F59-4217-8016-05DC917F4630

Q35838558-2B4D7E24-50E8-4905-B307-03259CF96B93

Q35838558-44A195B0-6C8C-4241-9C3D-00A59FEB4C0A

Q35838558-58E216A2-E9DB-4F95-B976-883AB70018CD

Q35838558-591BB3FF-5561-408B-9A73-7139696FE57C

Q35838558-6049BE34-3336-4C0B-8ADC-D90150CCC00D

Q35838558-605C3447-CAFF-4DDD-AAA3-CED6E165EAAD

Q35838558-639961C7-9EDF-4C11-9BEB-4EF98B604BAB

P304

Q35838558-F964EFFE-F35B-4C28-95AE-B51228D7DD61

P31

Q35838558-E1D69D14-BC6F-43B2-BAB6-A0BDB47C95A5

P356

Q35838558-A5EBCB3E-ED3E-4310-BB3E-BBB9D6294857

P407

Q35838558-DE87CF29-8D82-4AAD-8CBE-257B73090D41

P433

Q35838558-521C4B2A-764B-4C73-8D15-97C09BBC897C

P478

Q35838558-4DE23B36-B506-4049-9CD8-C96BB3F4436C

P577

Q35838558-A880ED41-3351-4E56-972B-500E48AF66F0

P698

Q35838558-45D45748-A26D-414F-BF2E-4C9CB2370FCE

P932

Q35838558-32C2E42F-C3AF-4CCD-B163-CA73AC7D25C9

P356

1078-0432.CCR-11-2202

P1433

Clinical Cancer Research

P1476

Development and use of integral assays in clinical trials

@en

P2093

Barbara A Conley

http://www.w3.org/2001/XMLSchema#string

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Michael Leblanc

http://www.w3.org/2001/XMLSchema#string

Richard L Schilsky

http://www.w3.org/2001/XMLSchema#string

P2860

Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.

Targeting the eicosanoid pathway in non-small-cell lung cancer.

Randomized clinical trials with biomarkers: design issues.

Use of archived specimens in evaluation of prognostic and predictive biomarkers

Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development

Bridging the gap: moving predictive and prognostic assays from research to clinical use

Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy

Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031

A cost-effectiveness approach to the qualification and acceptance of biomarkers.

Validation of analytic methods for biomarkers used in drug development

P304

1540-1546

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-2202

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22422406

http://www.w3.org/2001/XMLSchema#string

P932

3307146

http://www.w3.org/2001/XMLSchema#string